Molecular structure of rofecoxib
Find information on thousands of medical conditions and prescription drugs.

Vioxx

Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was used in the treatment of osteoarthritis, acute pain conditions, and dysmenorrhoea. Formerly marketed by Merck & Co. under the trade names Vioxx, Ceoxx and Ceeoxx, it was voluntarily withdrawn from the market in 2004 because of concerns about increased risk of heart attack and stroke. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. Worldwide, over two million people were prescribed Vioxx at the time. In the year before withdrawal, Merck had a sales revenue of US$2.5 billion from Vioxx.

Rofecoxib was available on prescription as tablets and as an oral suspension.

COX-2 selective inhibitor

Rofecoxib belongs to the group of NSAIDs known as COX-2 selective inhibitors or coxibs (CycloOXygenase-2 InhiBitors). Being COX-2 selective means that these drugs act specifically on one form of the cyclooxygenase (COX) enzyme, namely the COX-2, whereas previous NSAIDs inhibited both COX-1 and COX-2. This specificity allows rofecoxib and other COX-2 inhibitors to reduce inflammation and pain while minimizing undesired gastrointestinal adverse effects - peptic ulcers - that are common with non-selective NSAIDs such as aspirin, naproxen, and ibuprofen.

Interestingly, at the time of its withdrawal, rofecoxib was the only coxib with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs. This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the efficacy and adverse effect profiles of rofecoxib and naproxen. (Bombardier et al., 2000).

Adverse drug reactions

Aside from the reduced incidence of gastric ulceration, rofecoxib exhibits a similar adverse effect profile to other NSAIDs.

Withdrawal from the market

VIGOR study

The VIGOR study, published in 2000, had indicated a significant 4-fold increased risk of acute myocardial infarction (heart attack) in rofecoxib patients when compared with naproxen patients (0.4% vs 0.1%, RR 0.25) over the 12 month span of the study. There was no significant difference in the mortality from cardiovascular events between the two groups. Nor was there any significant difference in the rate of myocardial infarction between the rofecoxib and naproxen treatment groups in patients without high cardiovascular risk. The difference in overall risk was accounted for by the patients meeting the criteria for low-dose aspirin prophylaxis of secondary cardiovascular events (previous myocardial infarction, angina, cerebrovascular accident, transient ischemic attack, or coronary bypass), but who were excluded from taking low-dose aspirin in the initial design study. Once this risk was noted, Merck notified investigators in other rofecoxib studies to modify allow high-risk patients to take low-dose aspirin. (Bombardier et al., 2000)

Merck's scientists interpreted the finding as a protective effect of naproxen in reducing the risk of MI in high cardiovascular risk patients by 80 percent (which some commentators have noted would make naproxen three times as effective as aspirin). The results of the VIGOR study were submitted to the United States Food and Drug Administration (FDA) in February 2001, which led to the introduction, in April 2002, of warnings on Vioxx labelling concerning the increased risk of cardiovascular events (heart attack and stroke).

Read more at Wikipedia.org


[List your site here Free!]


Natural Alternatives To Vioxx, Celebrex & Other Anti-inflammatory Prescription Drugs $3.36 Natural alternatives to NSAIDs work on pain.(News) : An article from: Family Practice News $5.95
RX News: My Days at the FDA Advisory Committee Meetings on Vioxx : An article from: HealthFacts $10.00 Merck's heart attack.(Editorials)(Vioxx verdict is marketing's boomerang)(Editorial) : An article from: The Register-Guard (Eugene, OR) $5.95
Viewing the Vioxx verdict: suits become sole protection against big pharma firms.(COMMENTARY) : An article from: Los Angeles Business Journal $5.95 Latest on arthritis painkillers: Glucosamine, Celebrex, and Vioxx : An article from: HealthFacts $10.00
Vioxx Verdict Could Spur Big Changes : An article from: NJBIZ $10.00 A Benefit/Risk Analysis of Chronic Vioxx Use: Trading an Ulcer for a Heart Attack : An article from: HealthFacts $10.00
FDA's Vioxx move could hinder local biotech firms.(Food and Drug Administration) : An article from: San Diego Business Journal $5.95 Celebrex and Vioxx: Are they safer than the older anti-inflammatory drugs? : An article from: HealthFacts $10.00

Vioxx/Bextra controversy not driving arthritis sufferers to natural sector
Vioxx/Bextra controversy not driving arthritis sufferers to natural sector.(sales of over the counter drugs shows incremental growth after pulling out Vioxx/Bextra from the market)
Vioxx dust-up makes for OTC opening
Vioxx dust-up makes for OTC opening.(OTC/Natural Health)(over-the-counter, COX-2 inhibitors trends)
Drug safety issue addressed at Senate Vioxx hearing
Drug safety issue addressed at Senate Vioxx hearing.(Pharmacy News)(Congress.
Despite Vioxx recall concerns, doctors stick with cox-2 inhibitors
Despite Vioxx recall concerns, doctors stick with cox-2 inhibitors.
Target offering Vioxx refunds to all
Target offering Vioxx refunds to all.(Chain Pharmacy)
Vioxx's runaway jury
You'd think that a reputable company has at least the same chance of a fair trial as an accused murderer. But as the recent Angleton, Texas, jury's verdict against Vioxx shows, you'd be wrong. Th
Vioxx causes Merck 'adverse effects'
NEW YORK -- "If you suspect you or a loved one has suffered adverse effects resulting from Vioxx use ... recites one television commercial paid ...
Vying for Vioxx
Vying for Vioxx.(California residents sue Merck & Co.)

Home Contact Resources Exchange Links ebay